Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD

Executive Summary

Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair

You may also be interested in...



Medi-Span’s Price Alert (correction)

Average wholesale pricing database Price Alert is owned by Medi-Span, not First DataBank. "The Pink Sheet" incorrectly reported the owner of Price Alert in a story on Pfizer/Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (1"The Pink Sheet" May 31, 2004, p. 14)...

Medi-Span’s Price Alert (correction)

Average wholesale pricing database Price Alert is owned by Medi-Span, not First DataBank. "The Pink Sheet" incorrectly reported the owner of Price Alert in a story on Pfizer/Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (1"The Pink Sheet" May 31, 2004, p. 14)...

Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer

Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies

Related Content

UsernamePublicRestriction

Register

PS044082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel